Aequus Pharmaceuticals Inc. (CVE:AQS – Get Rating) Director Doug Janzen acquired 285,000 shares of the business's stock in a transaction on Wednesday, November 30th. The shares were purchased at an average price of C$0.04 per share, with a total value of C$11,400.00. Following the transaction, the director now owns 12,553,800 shares in the company, valued at approximately C$502,152.
Doug Janzen also recently made the following trade(s):
Get
Aequus Pharmaceuticals alerts:
- On Sunday, November 20th, Doug Janzen purchased 115,000 shares of Aequus Pharmaceuticals stock. The stock was bought at an average price of C$0.03 per share, with a total value of C$3,450.00.
Aequus Pharmaceuticals Stock Performance
Shares of AQS remained flat at C$0.03 during trading hours on Wednesday. 409,000 shares of the stock were exchanged, compared to its average volume of 64,529. The firm has a 50-day moving average of C$0.04 and a 200 day moving average of C$0.06. The company has a quick ratio of 0.70, a current ratio of 0.78 and a debt-to-equity ratio of 138.88. The stock has a market capitalization of C$3.98 million and a P/E ratio of -2.69. Aequus Pharmaceuticals Inc. has a 1-year low of C$0.02 and a 1-year high of C$0.12.
Aequus Pharmaceuticals (CVE:AQS – Get Rating) last announced its quarterly earnings results on Monday, August 29th. The company reported C($0.01) earnings per share (EPS) for the quarter. The firm had revenue of C$0.35 million for the quarter. Sell-side analysts forecast that Aequus Pharmaceuticals Inc. will post -0.1 earnings per share for the current year.
About Aequus Pharmaceuticals
(Get Rating)
Aequus Pharmaceuticals Inc, a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product.
Featured Articles
- Santa Claus Rally? Here's What Needs to Happen
- Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
- Dark Clouds Are Gathering For Cloud Stocks
- Hormel: Is This The Time To Buy?
- 3 Dividend Growers With Good 2023 Growth Prospects
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
